| Balance sheet (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 7.56B | 9.99B | 6.08B | 5.41B | 5.34B | 6.00B |
| Short-term investments | 68.00M | 0 | 1.18B | 973.00M | 1.18B | 1.41B |
| Receivables | 4.91B | 4.42B | 4.66B | 4.78B | 4.49B | 4.89B |
| Inventory | 1.77B | 1.71B | 1.79B | 1.51B | 1.62B | 1.68B |
| Total current assets | 18.34B | 19.17B | 16.09B | 14.44B | 14.77B | 16.00B |
| Property, plant and equipment | 5.61B | 5.41B | 5.32B | 5.47B | 5.12B | 4.97B |
| Goodwill and intangibles | 25.29B | 28.26B | 34.77B | 37.21B | 41.79B | 41.23B |
| Total assets | 59.02B | 58.99B | 62.13B | 63.17B | 67.95B | 68.41B |
| Accounts payable | 715.00M | 833.00M | 550.00M | 905.00M | 705.00M | 844.00M |
| Total current liabilities | 11.81B | 12.00B | 11.28B | 11.24B | 11.61B | 11.40B |
| Long-term debt | 22.13B | 24.90B | 23.19B | 22.96B | 25.18B | 28.64B |
| Total liabilities | 36.32B | 39.66B | 39.29B | 41.93B | 46.88B | 50.20B |
| Retained earnings | 13.73B | 11.50B | 16.30B | 15.69B | 16.32B | 14.38B |
| Shareholders' equity | 22.70B | 19.33B | 22.83B | 21.24B | 21.07B | 18.20B |
| Total debt | 24.94B | 26.71B | 24.99B | 25.23B | 26.70B | 31.40B |
| Net debt | 17.37B | 16.72B | 18.90B | 19.82B | 21.36B | 25.41B |
From Gilead Sciences's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.